Defitelio (defibrotide) is an oligonucleotide pharmaceutical. Defibrotide was first approved as Defitelio on 2013-10-18. It is used to treat hepatic veno-occlusive disease in the USA. It has been approved in Europe to treat hepatic veno-occlusive disease. Defitelio's patent is valid until 2032-06-22 (FDA).
|Indication||hepatic veno-occlusive disease|